PAIRS
Research type
Research Study
Full title
PARP Inhibitor Resistance Study
IRAS ID
297051
Contact name
Patricia Roxburgh
Contact email
Sponsor organisation
NHS GGC
Duration of Study in the UK
4 years, 3 months, 1 days
Research summary
PARP inhibitors (PARPi) are a new class of cancer treatment which have been shown to improve duration of disease control in women with advanced ovarian cancer when given as maintenance after chemotherapy. We know that not all ovarian cancer patients will benefit from PARPi maintenance and that many patients who benefit initially will develop PARPi resistant disease later. In this study, we aim to collect tumour samples from patients who have progressed on a PARPi and then by examination of their archival pre-PARPi tumour sample and their post-PARPi tumour sample, we will determine the reason for primary or acquired PARPi resistance. We will also collect blood samples from some patients to examine circulating markers of PARPi resistance. Understanding mechanisms of PARPi resistance and their relative contributions will allow us to spare patients unlikely to benefit, from PARPi-associated toxicity and design treatment strategies for PARPi resistant disease.
REC name
West of Scotland REC 5
REC reference
21/WS/0128
Date of REC Opinion
3 Dec 2021
REC opinion
Further Information Favourable Opinion